Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease (CVD) management company, announced today that two new patents for Myeloperoxidase (MPO) testing have been issued: U.S. Patent No. 9,581,597 and U.S. Patent No. 9,612,242. Cleveland HeartLab is the exclusive license holder for MPO testing, which is covered by a number of patents including these two newly issued patents. Originally discovered and developed at the Cleveland Clinic, MPO testing has been recognized in over 100 peer-reviewed publications as a key measure of vascular inflammation, which plays a key role in CVD and cardiovascular events. These new patents will add to Cleveland HeartLab’s already existing portfolio of intellectual property rights, which includes 26 issued patents and an additional 15 pending patent applications.